Newsletter Subject

A new hope for Alzheimer's

From

time.com

Email Address

TIME@newsletters.time.com

Sent On

Wed, Nov 30, 2022 09:03 PM

Email Preheader Text

Plus more health news | Email not displaying correctly? By Alice Park Senior Health Correspondent Re

Plus more health news | Email not displaying correctly? [View it in your browser.]( [Health Matters]( [A new drug shows promise for Alzheimer's]( By Alice Park Senior Health Correspondent Reporting on Alzheimer’s disease over past few decades has been both rewarding and heartbreaking. Hope for new treatments is often followed by disappointment when drugs don’t help patients as much as experts had hoped. But the latest glimmer of hope is getting major headlines today. The Japanese company Eisai reported at a conference last night that its drug lecanemab helped people with mild-to-moderate Alzheimer’s disease slow their cognitive decline by 27% compared to people who took a placebo. Even better, the effect increased over time. It's not an enormous improvement, but it's better than anything currently available. Here are the three most important things to know: - Lecanemab works by targeting amyloid, a protein that builds up in the brain during Alzheimer’s and eventually damages neurons. Other amyloid-based drugs—including the only approved treatment for the disease, aducanumab (or Aduhelm)—haven't been very effective. At the same conference, Roche reported that its anti-amyloid compound did not reduce amyloid enough to slow down progression of Alzheimer’s to a significant extent. - The drug comes with potential side effects, including inflammation in the brain and bleeding for those also taking anticoagulant drugs. Doctors say the inflammation is manageable if patients are monitored carefully and that the bleeding risk needs further study. - Eisai has filed for accelerated approval of the drug, and the U.S. Food and Drug Administration is expected to make a decision by early January. [READ THE STORY.]( Share the story What else to read [Many Asthma Patients Don’t Follow Their Medication Plans. Here’s How to Change That]( By Markham Heid A look at the latest measures to improve adherence, including new technologies and refinements to provider-patient interactions. [Read More »]( [How Israel Became the Global Center For Alternative Meat Tech]( By Aryn Baker / Tel Aviv, Israel Israel has become the center of lab-grown meat and alternative protein technologies, thanks to its geopolitics, climate, and culture. [Read More »]( [How the Pandemic Affected U.S. Birth Rates—and What Comes Next]( By Melissa S. Kearney and Phillip Levine At first there was a bust, then there was a boom, and now U.S. birth rates are back on their long-term, downward trend. [Read More »]( [Air Pollution Is Linked to Stillbirths—Especially in Poorer Countries]( By Jeffrey Kluger A new study finds a connection between fine-particle air pollution and the rate of stillbirths in low- and middle-income countries. [Read More »]( [Why Zumba Is Insanely Good Exercise]( By Markham Heid It's a party and a workout. (Originally published in 2017.) [Read More »]( One Last Read [The Dark Side of Hospice]( In theory, hospice care is unquestionably a good thing for society: dying with dignity, in as much comfort as possible, and with the ability to spend meaningful time with loved ones in one’s own home is surely better than languishing in the clinical setting of a hospital bed. But, as Ava Kofman writes in this deeply reported New Yorker story, it has become yet another part of the U.S. health care system that profiteers are exploiting for their own gain, with disregard to the patients (and their families) it was designed to help. [Read More »]( --------------------------------------------------------------- If you were forwarded this and want to sign up to receive it daily, [click here](. Today's newsletter was written by Alice Park and Elijah Wolfson and edited by Mandy Oaklander. [Want more from TIME? Sign up for our other newsletters.]( [Subscribe to TIME]( TIME may receive compensation for some links to products and services in this email. Offers may be subject to change without notice. Connect with TIME via [Facebook]( | [Twitter]( | [Newsletters]( [UNSUBSCRIBE]( [PRIVACY POLICY]( [YOUR CALIFORNIA PRIVACY RIGHTS]( TIME Customer Service, P.O. Box 37508, Boone, IA 50037-0508 Questions? Contact health@time.com Copyright © 2022 TIME USA, LLC. All rights reserved.

Marketing emails from time.com

View More
Sent On

31/10/2024

Sent On

29/10/2024

Sent On

28/10/2024

Sent On

24/10/2024

Sent On

15/10/2024

Sent On

03/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.